Skip to main content
OpenTrials

Clinical trial condition

Skin Diseases, Eczematous

Explore clinical trials studying Skin Diseases, Eczematous. Study availability and eligibility vary by location and protocol.

1,455 public trials 170 recruiting studies
Refine in advanced search Browse all conditions

Skin Diseases, Eczematous trial results

Completed

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

NCT03363854

Conditions
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, +9 more
Locations
  • University of Alabama-Birmingham Birmingham, Alabama, United States
  • California Dermatology & Clinical Research Institute Encinitas, California, United States
  • First OC Dermatology Fountain Valley, California, United States
  • Center for Dermatology Clinical Research Fremont, California, United States
View all 66 locations
View Trial Details
Completed

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

NCT03562377

Conditions
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, +9 more
Locations
  • Leo Pharma Investigational Site Fort Smith, Arkansas, United States
  • LEO Pharma Investigational Site Bakersfield, California, United States
  • Leo Pharma Investigational Site Beverly Hills, California, United States
  • Leo Pharma Investigational Site Fountain Valley, California, United States
View all 51 locations
View Trial Details
Completed

Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

NCT03526861

Conditions
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, +9 more
Locations
  • LEO Pharma Investigational Site Birmingham, Alabama, United States
  • LEO Pharma Investigational Site Fort Smith, Arkansas, United States
  • Leo Pharma Investigational Site Fountain Valley, California, United States
  • LEO Pharma Investigational Site Los Angeles, California, United States
View all 87 locations
View Trial Details
Completed

Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7

NCT03761537

Conditions
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, +9 more
Locations
  • Leo Pharma Investigationel Site Brussels, Belgium
  • Leo Pharma Investigationel Site Brussels, Belgium
  • Leo Pharma Investigationel Site Edegem, Belgium
  • Leo Pharma Investigationel Site Ghent, Belgium
View all 74 locations
View Trial Details
Completed

Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)

NCT05194540

Conditions
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, +9 more
Locations
  • LEO Pharma Investigator Birmingham, Alabama, United States
  • LEO Pharma Investigator Birmingham, Alabama, United States
  • LEO Pharma Investigator Fort Smith, Arkansas, United States
  • LEO Pharma Investigator Fountain Valley, California, United States
View all 29 locations
View Trial Details
Completed

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)

NCT03131648

Conditions
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, +9 more
Locations
  • Clinical Research Center of Alabama Birmingham, Alabama, United States
  • Tien Q. Nguyen, MD, Inc. Fountain Valley, California, United States
  • Dermatology Research Associates Los Angeles, California, United States
  • Quest Dermatology Research Northridge, California, United States
View all 123 locations
View Trial Details
Completed

Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis

NCT04587453

Conditions
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, +9 more
Locations
  • LEO Investigational Site Nagoya, Aichi-ken, Japan
  • LEO Investigational Site Ichikawa, Chiba, Japan
  • LEO Investigational Site Ichikawa-shi, Chiba, Japan
  • LEO Investigational Site Chikushino-shi, Fukuoka, Japan
View all 25 locations
View Trial Details
Completed

Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND

NCT03587805

Conditions
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, +9 more
Locations
  • LEO Pharma Investigational Site Birmingham, Alabama, United States
  • LEO Pharma Investigational Site Birmingham, Alabama, United States
  • LEO Pharma Investigational Site Mobile, Alabama, United States
  • LEO Pharma Investigational Site Fort Smith, Arkansas, United States
View all 309 locations
View Trial Details
Completed

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)

NCT03160885

Conditions
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, +9 more
Locations
  • Burke Pharmaceutical Research Hot Springs, Arkansas, United States
  • California dermatology Encinitas, California, United States
  • Advanced SkinCare Surgery & Med Center Fullerton, California, United States
  • USC Department of Dermatology Los Angeles, California, United States
View all 115 locations
View Trial Details

Related conditions